Evidence map›Paper›PMID 25795636›Full record

ReviewThe oncologist2015

Aprepitant and fosaprepitant: a 10-year review of efficacy and safety.

Matti Aapro, Alexandra Carides, Bernardo L Rapoport, Hans-Joachim Schmoll, Li Zhang, David Warr

3 registry-linked trialsAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in The oncologist, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 3 registered trials, which are not on this map. Cited by 65 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
65citing papers in PubMed, 4 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT06357234 phase2recruitingnot on this mapstarted 2025, after this paper: background citation

A Randomized Controlled Trial Comparing Aprepitant to Standard of Care for Postoperative Nausea and Vomiting Prophylaxis in Children and Adolescents Undergoing Scoliosis Surgery: The APRE-PONV Trial

TypeinterventionalSponsorIWK Health CentreRan2025 to 2027Enrolled100ConditionsSpinal Fusion, Nausea and Vomiting, Postoperative, AnesthesiaArmsAprepitant, Placebo
NCT06382012 phase2 / phase3recruitingnot on this mapstarted 2024, after this paper: background citation

Antiemetic Fosaprepitant To Remedy Nausea and Vomiting

TypeinterventionalSponsorMontefiore Medical CenterRan2024 to 2027Enrolled200ConditionsNausea and Vomiting, Nausea, VomitingArmsFosaprepitant 150 mg, Ondansetron 4 mg
NCT06740812 phase4not yet recruitingnot on this mapstarted 2026, after this paper: background citation

Broadening Antiemetics Research by Comparing the Effectiveness of Fosaprepitant and Metoclopramide: A Randomized Control Trial

TypeinterventionalSponsorMontefiore Medical CenterRan2026 to 2027Enrolled212ConditionsNausea and Vomiting, Nausea, VomitingArmsFosaprepitant for Injection, Metoclopramide Injection
3 · Its place in the literature

Who cites it

65 citing papers in PubMed, 4 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Trial
  6. Trial
  7. Trial
  8. Trial
  9. Trial
  10. Chemotherapy-induced nausea and vomiting: incidence and characteristics of persistent symptoms and future directions NCCTG N08C3 (Alliance).Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2016
    Trial
  11. Observational
  12. Article
  13. Article
  14. Article
  15. Observational
  16. Article
  17. Review
  18. Review
  19. Review
  20. Review

5 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Matti AaproClinique de Genolier, Genolier, Switzerland; Temple University, Philadelphia, Pennsylvania, USA; The Medical Oncology Center of Rosebank, Johannesburg, South Africa; University Clinic Halle, Halle, Germany; Sun Yat-Sen University Cancer Center, Guangzhou, Guangdong, People's Republic of China; Princess Margaret Cancer Centre, Toronto, Ontario, Canada maapro@genolier.net.
Alexandra CaridesClinique de Genolier, Genolier, Switzerland; Temple University, Philadelphia, Pennsylvania, USA; The Medical Oncology Center of Rosebank, Johannesburg, South Africa; University Clinic Halle, Halle, Germany; Sun Yat-Sen University Cancer Center, Guangzhou, Guangdong, People's Republic of China; Princess Margaret Cancer Centre, Toronto, Ontario, Canada.
Bernardo L RapoportClinique de Genolier, Genolier, Switzerland; Temple University, Philadelphia, Pennsylvania, USA; The Medical Oncology Center of Rosebank, Johannesburg, South Africa; University Clinic Halle, Halle, Germany; Sun Yat-Sen University Cancer Center, Guangzhou, Guangdong, People's Republic of China; Princess Margaret Cancer Centre, Toronto, Ontario, Canada.
Hans-Joachim SchmollClinique de Genolier, Genolier, Switzerland; Temple University, Philadelphia, Pennsylvania, USA; The Medical Oncology Center of Rosebank, Johannesburg, South Africa; University Clinic Halle, Halle, Germany; Sun Yat-Sen University Cancer Center, Guangzhou, Guangdong, People's Republic of China; Princess Margaret Cancer Centre, Toronto, Ontario, Canada.
Li ZhangClinique de Genolier, Genolier, Switzerland; Temple University, Philadelphia, Pennsylvania, USA; The Medical Oncology Center of Rosebank, Johannesburg, South Africa; University Clinic Halle, Halle, Germany; Sun Yat-Sen University Cancer Center, Guangzhou, Guangdong, People's Republic of China; Princess Margaret Cancer Centre, Toronto, Ontario, Canada.
David WarrClinique de Genolier, Genolier, Switzerland; Temple University, Philadelphia, Pennsylvania, USA; The Medical Oncology Center of Rosebank, Johannesburg, South Africa; University Clinic Halle, Halle, Germany; Sun Yat-Sen University Cancer Center, Guangzhou, Guangdong, People's Republic of China; Princess Margaret Cancer Centre, Toronto, Ontario, Canada.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Chemotherapy-induced nausea and vomiting (CINV) is a common adverse event associated with anticancer treatment that can have a significant adverse impact on patient health-related quality of life and that can potentially undermine the effectiveness of chemotherapy. Traditional regimens to prevent CINV generally involved a combination of a corticosteroid plus a 5-hydroxytryptamine (5HT3) receptor antagonist (RA). In the past 10 years, antiemetic treatment has greatly advanced with the availability of the neurokinin-1 receptor antagonist (NK1 RA) aprepitant and its prodrug fosaprepitant. NK1 RAs have a different mechanism of action in CINV than corticosteroids and 5HT3 RAs, thus their use can complement traditional antiemetic drugs and can enhance control of CINV. This review examined accumulated data regarding the safety and efficacy of aprepitant and fosaprepitant over the decade since the first regulatory approval. Data from key studies of aprepitant and fosaprepitant in the prevention of CINV in patients receiving moderately and highly emetogenic chemotherapy were explored, as were recommendations in currently available guidelines for their use. In addition, their use as antiemetic therapy in special patient populations was highlighted. Future perspectives on potential uses of aprepitant and fosaprepitant for indications other than CINV are presented.

Indexed as

Administration, IntravenousAdministration, OralAntiemeticsAntineoplastic AgentsAprepitantDrug InteractionsGuidelines as TopicHumansMorpholinesNauseaStem Cell TransplantationVomitingAntiemeticsAntineoplastic AgentsAprepitantfosaprepitantMorpholinesAprepitantChemotherapy-induced nausea and vomitingFosaprepitantHighly emetogenic chemotherapyModerately emetogenic chemotherapyNeurokinin-1 receptor antagonist

Identifiers

PMID25795636
PMCPMC4391760

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.